Characteristic | British Columbia | Saskatchewan | ||
---|---|---|---|---|
No. (%) of prescriptions/recipients | 95% CI | No. (%) of prescriptions/recipients | 95% CI | |
Prescriptions | 2 100 947 (100.0) | 585 476 (100.0) | ||
Route of administration | ||||
Oral | 688 522 (32.8) | 32.7 to 32.8 | 202 071 (34.5) | 34.4 to 34.6 |
Intravenous/other | 1 412 425 (67.2) | 67.2 to 67.3 | 383 405 (65.5) | 65.4 to 65.6 |
Indication | ||||
Breast cancer | 573 376 (27.3) | 27.2 to 27.4 | 124 971 (21.3) | 21.2 to 21.5 |
Colorectal cancer | 420 224 (20.0) | 19.9 to 20.1 | 176 161 (30.1) | 30.0 to 30.2 |
Lung cancer | 106 866 (5.1) | 5.1 to 5.1 | 33 995 (5.8) | 5.7 to 5.9 |
Prostate cancer | 197 864 (9.4) | 9.4 to 9.5 | 51 813 (8.8) | 8.8 to 8.9 |
Other cancer | 802 617 (38.2) | 38.1 to 38.3 | 198 536 (33.9) | 33.8 to 34.0 |
Recipients | 103 680 (100.0) | 23 108 (100.0) | ||
Sex | ||||
Male | 48 201 (46.5) | 46.2 to 46.8 | 11 240 (48.6) | 48.0 to 49.3 |
Female | 55 479 (53.5) | 53.2 to 53.8 | 11 868 (51.4) | 50.7 to 52.0 |
Age, yr, mean ± SD | ||||
Age, yr | 64.9 ± 13.6 | 64.8 to 65.0 | 65.5 ± 13.3 | 65.3 to 65.7 |
< 50 | 13 619 (13.1) | 12.9 to 13.3 | 2733 (11.8) | 11.4 to 12.2 |
50–59 | 20 196 (19.5) | 19.2 to 19.7 | 4453 (19.3) | 18.8 to 19.8 |
60–69 | 28 377 (27.4) | 27.1 to 27.6 | 6184 (26.8) | 26.2 to 27.3 |
70–79 | 26 501 (25.6) | 25.3 to 25.8 | 6385 (27.6) | 27.1 to 28.2 |
≥ 80 | 14 987 (14.4) | 14.2 to 14.7 | 3353 (14.5) | 14.1 to 15.0 |
Cancer site | ||||
Breast | 29 552 (28.5) | 28.2 to 28.8 | 6059 (26.2) | 25.7 to 26.8 |
Colorectal | 9861 (9.5) | 9.3 to 9.7 | 2354 (10.2) | 9.8 to 10.6 |
Lung | 7624 (7.4) | 7.2 to 7.5 | 2081 (9.0) | 8.6 to 9.4 |
Prostate | 17 516 (16.9) | 16.7 to 17.1 | 4233 (18.3) | 17.8 to 18.8 |
Other | 39 127 (37.7) | 37.4 to 38.0 | 8381 (36.3) | 35.6 to 36.9 |
Note: CI = confidence interval, SD = standard deviation.